A Phase 2 interventional study of Niclosamide Oral Tablet and Placebo in COVID, sponsored by Entero Therapeutics. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-21.
Sponsored by Entero Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 2, multicentre, randomized, double blind, 2 arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms.
Entero Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Continued SOC therapy together with Niclosamide tablets for 14 days
Drug: Niclosamide Oral Tablet
Continued SOC therapy together with placebo tablets matching niclosamide
Drug: Placebo
Continued SOC therapy together with niclosamide TID for 14 days
Continued SOC therapy together with placebo tablets matching niclosamide for 14 days
The primary endpoint is the rate of faecal SARS-CoV-2 virus clearance (rectal swab or stool sample) assessed by RT-PCR in the niclosamide group, compared to the placebo group
Time frame: From Day 1 to 42
No study locations are listed for this record.
Ran from Jan 2022 to primary completion in Jan 2022, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niclosamide
Entero Therapeutics